Along these lines, the FERM domain mutation of JAK2 (JAK2 L224E), which inhibits the PK‐PK interaction, significantly inhibits TpoR dimerization even in the context of the activating PK domain mutation JAK2 V617F (driver mutation in MPN). The gene discussed is MPL; the disease is myeloproliferative neoplasm.